OTCPK:SYNM.F

Stock Analysis Report

Executive Summary

Synthetic MR AB (publ) develops and markets software solutions for magnetic resonance imaging (MRI) in Sweden and internationally.

Snowflake

Fundamentals

Exceptional growth potential with flawless balance sheet.

Risks

  • SyntheticMR is covered by less than 3 analysts.

Share Price & News

How has SyntheticMR's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0%

OTCPK:SYNM.F

2.1%

US Healthcare Services

1.1%

US Market


1 Year Return

n/a

OTCPK:SYNM.F

7.7%

US Healthcare Services

2.1%

US Market

No trading data on SYNM.F.

No trading data on SYNM.F.


Share holder returns

SYNM.FIndustryMarket
7 Day0%2.1%1.1%
30 Day0%-4.7%3.7%
90 Day0%-4.6%2.3%
1 Yearn/a7.7%7.7%4.4%2.1%
3 Yearn/a51.1%50.8%47.0%37.4%
5 Yearn/a49.2%48.3%61.6%43.8%

Price Volatility Vs. Market

How volatile is SyntheticMR's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is SyntheticMR undervalued based on future cash flows and its price relative to the stock market?

50%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

SyntheticMR's share price is below the future cash flow value, and at a moderate discount (> 20%).

SyntheticMR's share price is below the future cash flow value, and at a substantial discount (> 40%).


Price Based on Earnings

SyntheticMR is overvalued based on earnings compared to the US Healthcare Services industry average.

SyntheticMR is overvalued based on earnings compared to the United States of America market.


Price Based on Expected Growth

SyntheticMR is poor value based on expected growth next year.


Price Based on Value of Assets

SyntheticMR is overvalued based on assets compared to the US Healthcare Services industry average.


Next Steps

Future Growth

How is SyntheticMR expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

46.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

SyntheticMR's revenue is expected to grow significantly at over 20% yearly.

SyntheticMR's earnings are expected to grow significantly at over 20% yearly.

SyntheticMR's revenue growth is expected to exceed the United States of America market average.

SyntheticMR's earnings growth is expected to exceed the United States of America market average.

SyntheticMR's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

SyntheticMR is expected to make outstanding use of shareholders’ funds in the future (Return on Equity greater than 40%).


Next Steps

Past Performance

How has SyntheticMR performed over the past 5 years?

66.9%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

SyntheticMR has delivered over 20% year on year earnings growth in the past 5 years.

SyntheticMR's 1-year earnings growth is less than its 5-year average (14.8% vs 66.9%)

SyntheticMR's earnings growth has exceeded the US Healthcare Services industry average in the past year (14.8% vs 5.6%).


Return on Equity

SyntheticMR has efficiently used shareholders’ funds last year (Return on Equity greater than 20%).


Return on Assets

SyntheticMR used its assets more efficiently than the US Healthcare Services industry average last year based on Return on Assets.


Return on Capital Employed

SyntheticMR has become profitable over the past 3 years. This is considered to be a significant improvement in its use of capital (Return on Capital Employed).


Next Steps

Financial Health

How is SyntheticMR's financial position?


Financial Position Analysis

SyntheticMR is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

SyntheticMR has no long term commitments.


Debt to Equity History and Analysis

SyntheticMR has no debt.

SyntheticMR currently has no debt however we can't compare to 5 years ago as we have no data for that period.

SyntheticMR has no debt, it does not need to be covered by operating cash flow.

SyntheticMR has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet

Low level of unsold assets.

SyntheticMR has no debt, it does not need to be covered by short term assets.


Next Steps

Dividend

What is SyntheticMR's current dividend yield, its reliability and sustainability?

1.40%

Expected Dividend Yield


Dividend Yield and Payments Analysis

SyntheticMR's pays a lower dividend yield than the bottom 25% of dividend payers in United States of America (1.49%).

SyntheticMR's dividend is below the markets top 25% of dividend payers in United States of America (3.84%).

SyntheticMR is not paying a notable dividend for United States of America, therefore no need to check if the payments are stable.

SyntheticMR is not paying a notable dividend for United States of America, therefore no need to check if the payments are increasing.


Current Payout to Shareholders

No need to calculate the sustainability of SyntheticMR's dividends as it is not paying a notable one for United States of America.


Future Payout to Shareholders

Dividends after 3 years are expected to be well covered by earnings (2.6x coverage).


Next Steps

Management

What is the CEO of SyntheticMR's salary, the management and board of directors tenure and is there insider trading?

7.4yrs

Average board tenure


CEO

Ulrik Harrysson 0

0.08yrs

Tenure

0

Mr. Ulrik Harrysson has been the Chief Executive Officer at SyntheticMR AB, since July 1, 2019. He served as Senior Vice President of Global Marketing and Sales at Hermes Medical Solutions AB. Earlier in h ...


Board Age and Tenure

7.4yrs

Average Tenure

58.5yo

Average Age

The tenure for the SyntheticMR board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Recent Insider Transactions

Buykr136,71715 Aug 19
Johan Sedihn
EntityIndividual
Role
Member of the Board of Directors
Director
Shares5,000
Max Pricekr27.44
Buykr64,33228 Feb 19
Yvonne Mårtensson
EntityIndividual
Role
Member of the Board of Directors
Director
Shares2,000
Max Pricekr32.17
Sellkr998,25922 Jan 19
Staffan Persson
EntityIndividual
Role
Chairman of the Board
Chairman of the Board
Shares30,000
Max Pricekr33.28

Ownership Breakdown


Management Team

  • Bertus Warntjes (46yo)

    Head of Innovation & Director

    • Tenure: 12.6yrs
    • Compensation: kr928.00k
  • Fredrik Jeppsson (37yo)

    CFO & Head of Investor Relations

    • Tenure: 0yrs
  • Jonas Hurtig (48yo)

    Head of Marketing & Commercial Affairs

    • Tenure: 0yrs
  • Lisa Warnroth (38yo)

    Head of QA/RA

    • Tenure: 0yrs
  • Ulrik Harrysson

    Chief Executive Officer

    • Tenure: 0.08yrs
  • Markus Malmgren (41yo)

    Head of Research & Development

    • Tenure: 0yrs

Board Members

  • Yvonne Mårtensson (66yo)

    Director

    • Tenure: 3.3yrs
    • Compensation: kr133.00k
  • Johan Sedihn (54yo)

    Director

    • Tenure: 8.6yrs
    • Compensation: kr133.00k
  • Staffan Persson (63yo)

    Chairman of the Board

    • Tenure: 6.2yrs
    • Compensation: kr206.00k
  • Bertus Warntjes (46yo)

    Head of Innovation & Director

    • Tenure: 12.6yrs
    • Compensation: kr928.00k

Company Information

SyntheticMR AB (publ)'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: SyntheticMR AB (publ)
  • Ticker: SYNM.F
  • Exchange: OTCPK
  • Founded: 2007
  • Industry: Health Care Technology
  • Sector: Healthcare
  • Market Cap: kr1.111b
  • Listing Market Cap: kr116.333m
  • Shares outstanding: 4.04m
  • Website: https://www.syntheticmr.com

Number of Employees


Location

  • SyntheticMR AB (publ)
  • Storgatan 11
  • Linköping
  • Östergötland County
  • 582 23
  • Sweden

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
SYNTNGM (Nordic Growth Market)YesShare CapitalSESEKOct 2013
SYNM.FOTCPK (Pink Sheets LLC)YesShare CapitalUSUSDOct 2013

Biography

Synthetic MR AB (publ) develops and markets software solutions for magnetic resonance imaging (MRI) in Sweden and internationally. The company offers SyMRI IMAGE, a software solution that optimizes MRI wor ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/14 00:44
End of Day Share Price2019/05/16 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.